1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Purdue Pharma L.P. - Product Pipeline Review - 2015

Purdue Pharma L.P. - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

Purdue Pharma L.P. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Purdue Pharma L.P. - Product Pipeline Review - 2015’, provides an overview of the Purdue Pharma L.P.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Purdue Pharma L.P.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Purdue Pharma L.P. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Purdue Pharma L.P.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Purdue Pharma L.P.’s pipeline products

Reasons to buy

- Evaluate Purdue Pharma L.P.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Purdue Pharma L.P. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Purdue Pharma L.P.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Purdue Pharma L.P. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Purdue Pharma L.P.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Purdue Pharma L.P. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Purdue Pharma L.P. - Product Pipeline Review - 2015
Table of Contents
Purdue Pharma L.P. Snapshot 5
Purdue Pharma L.P. Overview 5
Key Information 5
Key Facts 5
Purdue Pharma L.P. - Research and Development Overview 6
Key Therapeutic Areas 6
Purdue Pharma L.P. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Purdue Pharma L.P. - Pipeline Products Glance 15
Purdue Pharma L.P. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Purdue Pharma L.P. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Purdue Pharma L.P. - Drug Profiles 18
(naloxone hydrochloride + oxycodone hydrochloride) ER 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
PRC-062 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
V-116517 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Purdue Pharma L.P. - Pipeline Analysis 22
Purdue Pharma L.P. - Pipeline Products by Target 22
Purdue Pharma L.P. - Pipeline Products by Route of Administration 23
Purdue Pharma L.P. - Pipeline Products by Molecule Type 24
Purdue Pharma L.P. - Pipeline Products by Mechanism of Action 25
Purdue Pharma L.P. - Recent Pipeline Updates 26
Purdue Pharma L.P. - Dormant Projects 27
Purdue Pharma L.P. - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
licostinel 28
Purdue Pharma L.P. - Company Statement 29
Purdue Pharma L.P. - Locations And Subsidiaries 30
Head Office 30
Other Locations and Subsidiaries 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Purdue Pharma L.P., Key Information 5
Purdue Pharma L.P., Key Facts 5
Purdue Pharma L.P. - Pipeline by Indication, 2015 7
Purdue Pharma L.P. - Pipeline by Stage of Development, 2015 8
Purdue Pharma L.P. - Monotherapy Products in Pipeline, 2015 9
Purdue Pharma L.P. - Combination Treatment Modalities in Pipeline, 2015 10
Purdue Pharma L.P. - Partnered Products in Pipeline, 2015 11
Purdue Pharma L.P. - Partnered Products/ Combination Treatment Modalities, 2015 12
Purdue Pharma L.P. - Out-Licensed Products in Pipeline, 2015 13
Purdue Pharma L.P. - Out-Licensed Products/ Combination Treatment Modalities, 2015 14
Purdue Pharma L.P. - Pre-Registration, 2015 15
Purdue Pharma L.P. - Phase III, 2015 16
Purdue Pharma L.P. - Phase II, 2015 17
Purdue Pharma L.P. - Pipeline by Target, 2015 22
Purdue Pharma L.P. - Pipeline by Route of Administration, 2015 23
Purdue Pharma L.P. - Pipeline by Molecule Type, 2015 24
Purdue Pharma L.P. - Pipeline Products by Mechanism of Action, 2015 25
Purdue Pharma L.P. - Recent Pipeline Updates, 2015 26
Purdue Pharma L.P. - Dormant Developmental Projects,2015 27
Purdue Pharma L.P. - Discontinued Pipeline Products, 2015 28
Purdue Pharma L.P., Other Locations 30
Purdue Pharma L.P., Subsidiaries 31

List of Figures
Purdue Pharma L.P. - Pipeline by Top 10 Indication, 2015 7
Purdue Pharma L.P. - Pipeline by Stage of Development, 2015 8
Purdue Pharma L.P. - Monotherapy Products in Pipeline, 2015 9
Purdue Pharma L.P. - Partnered Products in Pipeline, 2015 11
Purdue Pharma L.P. - Out-Licensed Products in Pipeline, 2015 13
Purdue Pharma L.P. - Pipeline by Top 10 Target, 2015 22
Purdue Pharma L.P. - Pipeline by Top 10 Route of Administration, 2015 23
Purdue Pharma L.P. - Pipeline by Top 10 Molecule Type, 2015 24
Purdue Pharma L.P. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.